Amarin Corp Plc (AMRN)

[north40000]

I understood your original post, jasbg. No problem.

I posted that article to illustrate the size of the “obesity” market in which Amarin and a “re-purposed” Vascepa may be able to participate. Some folks have published their weight loss data here that seems to correlate with introduction of Vascepa into their system. I have posted that my weight loss has been ~ 30-35 lbs since April 2013.

Scientists at LLY, NVO, PFE, MRK, AMGN now recognize that a “cascade of issues” seem to be associated with excess weight and diabetes in humans—heart failure, NASH and Alzheimer’s among them. They have conducted clinical trials with old and new drugs to obtain FDA approval of meds to treat obesity.

Will Amarin and/or Kaiser-Permanente collect/release any patients’ weight loss data in 2022/2023 from the Reduce-It or Mitigate clinical trials? Will University of Wisconsin investigators collect/release weight loss data from the patients treated with Vascepa in their Alzheimer’s trial?